SciELO - Scientific Electronic Library Online

 
vol.25 número2Manejo farmacológico del dolor agudo postoperatorio en España. Datos de la encuesta nacional de la Sociedad Española del Dolor (SED)Venlafaxina en el tratamiento del dolor neuropático índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista de la Sociedad Española del Dolor

versión impresa ISSN 1134-8046

Resumen

GARNICA-TELLEZ, D.; ARIAS-VAZQUEZ, P.I.  y  RAMIREZ-WAKAMATZU, M.A.. Efficacy of antihomotoxic medicine in treatment of cervical miofascial síndrome and shoulder girdle: comparative study versus botulinum toxin type A. Rev. Soc. Esp. Dolor [online]. 2018, vol.25, n.2, pp.86-93. ISSN 1134-8046.  https://dx.doi.org/10.20986/resed.2017.3594/2017.

Introduction:

Myofascial pain syndrome is a common cause of muscle pain in cervical region and shoulder girdle. Treatment has included conservative means and invasive procedures; conservative means include drugs, modalities of physical therapy, massage and therapeutic exercise; Invasive procedures include dry nedling and trigger point injections of various substances such as botulinum toxin type A, steroids and local anesthetics and even has been reported effective with the injection of complex homeopathic medicines known as antihomotoxic drugs.

Objective:

To compare the effectiveness of the intramuscular injections in trigger points using a Botulinum toxin type A versus antihomotóxic drugs.

Materials and methods:

We conducted a pilot study, longitudinal, prospective, randomized and blind, type controlled clinical trial, which included 31 patients with diagnosis of myofascial syndrome of cervical region and shoulder girdle, divided in 3 groups; each group received intramuscular injections in trigger points. One group was treated with botulinum toxin type A with a dose of 10U by trigger point, another group was treated with a combination of antihomotoxic drugs that included a mixture of Traumeel(r) S, Spascupreel(r), Gels Homaccord(r) y Lymphomyosot(r) at a rate of 1 ml of this combination by trigger point; the third group received placebo treatment with saline solution at 0.9 % at the rate of 1 ml. for trigger point. The three groups were evaluated mobility, muscular strength, pain intensity with EVA, number of trigger points and disability index of the neck at the start of treatment and at 6 weeks.

Results: It was observed a decrease of pain and the number of trigger points in the 3 groups, however it was only statistically significant in the group treated with antihomotoxic drugs.

Conclusions:

The use of antihomotoxic drugs applied by intramuscular injection in the trigger points can be an effective treatment option in patients with cervical myofascial pain syndrome.

Palabras clave : Myofascial pain; antihomotoxic medicine; botulinum toxin type A.

        · resumen en Español     · texto en Español     · Español ( pdf )